Seeking Alpha: Endo Health Has A Lot Of Work To Do

How do you ruin a specialty pharmaceutical business? Take a ridiculously lucrative stream of free cash flow generated by a strong pain fra...

Investopedia: A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

Confirming a pretty active recent rumor mill in the generic and specialty drug space, Actavis (NYSE: ACT ) announced on Monday that it had ...

Investopedia: Teva Still Too Cheap, But Still Too Uncertain

The story on the generics giant Teva Pharmaceutical (Nasdaq: TEVA ) really hasn't changed all that much over the past year. For invest...